GBM immunotherapy: Exploring molecular and clinical frontiers.

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Research

Background:

• Glioblastoma (GBM) is an aggressive primary brain tumor with limited treatment options and poor survival.
• Immunotherapy is emerging as a preferred treatment for GBM due to improved patient outcomes compared to conventional therapies.

Purpose of the Study:

• To review clinical trials of various GBM immunotherapeutic approaches.
• To assess the efficacy and safety of immunotherapies including immune checkpoint blockers (ICBs), CAR T-cell therapy, cancer vaccines, and adoptive cell therapy.
• To discuss challenges and combinatorial strategies for enhancing immunotherapy in GBM.

Main Methods:

• Literature review of clinical trials on GBM immunotherapy.
• Analysis of efficacy and safety data for different immunotherapeutic strategies.
• Exploration of challenges such as the immunosuppressive microenvironment, tumor heterogeneity, and the blood-brain barrier (BBB).

Main Results:

• Various immunotherapies, including ICBs and CAR T-cell therapy, have shown potential in clinical trials.
• Significant challenges like the immunosuppressive tumor microenvironment and the BBB impede therapeutic efficacy.
• Combinatorial approaches are being investigated to overcome these challenges.

Conclusions:

• Immunotherapy holds significant clinical potential for treating GBM.
• Addressing challenges through combinatorial strategies is crucial for maximizing the benefits of GBM immunotherapy.
• This review provides current knowledge and future perspectives on GBM immunotherapy.